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Abstract The p21-activated protein kinases (PAKs) may 
participate in signalling from Cdc42/Racl to the stress-regulated 
MAPKs (SAPKs/JNKs and p38-/HOG-l-related-MAPKs). We 
characterized the expression and regulation of rxPAK in cultured 
ventricular myocytes. aPAK was specifically immunoprecipi-
tated from myocyte extracts. High basal aPAK activity was 
detected in unstimulated myocytes. Its activity was increased 
rapidly ( < 30 s) by hyperosmotic shock in the presence of 
okadaic acid, and was maximal by 3 min (187 ± 7 % relative to 
unstimulated cells). Endothelin-1 and interleukin-lß, which also 
activate SAPKs/JNKs, did not increase rxPAK activity and 
presumably act through different PAK isoforms or other 
mechanisms. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Mitogen-activated protein kinase (MAPK) cascades are ac-
tivated in eukaryotic cells in response to external stimuli and 
are important in signalling to the nucleus (reviewed [ 1 ^ ] ) . 
Three M A P K cascades have been identified in rat heart and 
cultured ventricular myocytes from neonatal rat hearts. The 
extracellularly regulated kinases (ERKs) are activated by 
growth factors and hypertrophic agonists such as endothe-
lin-1 (ET-1) [5,6]. The stress-activated protein kinases (SAPKs 
or JNKs , for c-Jun N-terminal kinases) are activated by cel-
lular stress (hyperosmotic stress, protein synthesis inhibitors 
or ischaemia/reperfusion) and by ET-1 [7,8]. The p38- or 
HOG-1-related MAPK(s) is activated by ischaemia [8]. 
The p21-activated protein kinases (PAKs) are a family of 
protein Ser-/Thr-kinases that may be involved in the upstream 
activation of the SAPK/JNK and p38-MAPK cascades (re-
viewed [4]). At least three members have been identified. 
a P A K (also known as PAK1 and human PAK65 [9]) was first 
identified in rat brain as a kinase which interacted with the 
active (GTP-bound) forms of the Rho family G proteins, 
Cdc42 and Rac l [10]. This interaction results in the autophos-
phorylation and activation of rxPAK. Other PAKs include 
ßPAK [11] (also known as mouse P A K 3 [12]) and yPAK 
[13] (also known as PAK I [14]). 
Very little is known about the activation of PAKs, though 
yPAK is activated in platelets by thrombin [13]. The down-
stream targets of the PAKs and the coupling mechanism to 
the SAPK/JNK and p38-MAPK cascades are currently un-
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known. Here, we have characterized the expression of one 
PAK isoforms ( aPAK) in neonatal rat ventricular myocytes 
in primary culture, and studied the activation of this protein 
kinase in response to stimuli which activate the SAPK/JNK 
cascade in these cells. 
2. Materials and methods 
2.1. Materials 
The polyclonal aPAK antibody aPAK(N-20) raised to residues 2— 
21 was from Santa Cruz Biotechnology. [y-32P]ATP, prestained mo-
lecular mass markers, biotinylated anti-rabbit IgG, ECL blotting re-
agents and Hyperfilm MP were from Amersham International. SDS-
PAGE reagents were from Bio-Rad. Nitrocellulose (Schleicher & 
Schuell, 0.45 am) was from Anderman & Co. Protein A-Sepharose 
and other biochemicals were from Sigma. Myocytes were isolated 
from the ventricles of neonatal Sprague-Dawley rat hearts essentially 
as previously described [15] and cultured at a density of 1400 cells/ 
mm2 for 90 h on 60 mm gelatin-coated dishes with one medium 
change at 66 h. The cells were incubated for 24 h in serum-free me-
dium and then assayed for aPAK activity after exposure to agonists. 
2.2. Assay ofaPAK 
Myocytes were unstimulated (i.e. no medium change), exposed to a 
medium change (control cells), subjected to hyperosmotic shock (0.5 
M sorbitol) in the presence or absence of the PP1/PP2A protein phos-
phatase inhibitor okadaic acid (0.2 uM), or exposed to ET-1 (0.1 uM) 
or interleukin-lß (IL-lß, 100 ng/ml) at 37°C. The medium was re-
moved and the cells scraped into 0.4 ml of ice-cold extraction buffer 
consisting of 20 mM n-octyl ß-D-glucopyranoside and 1% (v/v) Triton 
X-100 in buffer A (10 mM Tris-HCl pH 7.4, 5 mM EDTA, 50 mM 
NaF, 50 mM NaCl, 2 mM Na3V04 , 0.1% (w/v) fatty acid-free bovine 
serum albumin, 20 ug/ml aprotinin). The samples were extracted on 
ice (10 min) and centrifuged (5 min, lOOOOXg, 4°C). The supernatants 
were incubated with 4 ul (0.4 ug) aPAK antibody in the presence or 
absence of competing peptide (0.8 ug) on a rotating wheel (2 h, 4°C). 
Protein A-Sepharose was added (20 ul of a 50% slurry in buffer A) 
and the samples rotated for another 1 h. The samples were centrifuged 
(1 min, lOOOOXg, 4°C), the supernatants removed and the pellet 
washed in buffer A (3X150 ul, 4°C). The pellets were then washed 
in 0.4 ml aPAK assay buffer (20 mM HEPES pH 7.6, 25 mM ß-
glycerophosphate, 20 mM MgCl2, 1 mM MnCl2, 0.1 mM Na3V04 , 
2 mM dithiothreitol) and resuspended in 50 u.1 aPAK assay buffer 
containing 10 ug myelin basic protein (MBP). Samples were assayed 
for activity with 10 ul [y-32P]ATP (20 uM, 25 uCi/ml) for 20 min at 
30°C. The entire assay mixtures were spotted onto Whatman 3MM 
papers which were washed in 5%> trichloroacetic acid (4X15 min). 32P 
incorporation into MBP was determined by Cerenkov counting. 
2.3. Western blotting 
Myocytes were extracted in extraction buffer (150 ul) as above and 
supernatants retained. For total extracts, the supernatants were boiled 
with 0.33 vol. SDS sample buffer (10% (w/v) SDS, 13% (v/v) glycerol, 
300 mM Tris-HCl pH 6.8, 130 mM dithiothreitol, 0.2% bromophenol 
blue). aPAK was immunoprecipitated from supernatants with 4 ul of 
antibody and 20 ul 50% (v/v) Protein A-Sepharose in buffer A as 
described above. The washed immunoprecipitates (resuspended in 
150 ul Buffer A) or the aPAK immunodepleted supernatants were 
boiled with 0.33 vol. SDS sample buffer. Proteins (25 u.1) were sepa-
rated by SDS-PAGE on 8% (w/v) polyacrylamide gels and transferred 
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electrophoretically to nitrocellulose [16]. Non-specific binding sites 
were blocked with 5% (w/v) non-fat milk powder in phosphate-buf-
fered saline containing 0.05% Tween-20 (PBST) and the blots were 
incubated with aPAK antibody (1:100 dilution in blocking solution, 
overnight, 4°C). After washing in PBST (3X5 min) the blots were 
incubated with horseradish peroxidase-linked anti-rabbit IgG 
(1:5000 dilution in PBST containing 1% (w/v) non-fat milk powder, 
1 h, room temperature). The blots were washed again in PBST (3X5 
min) and the bands were detected using the Amersham International 
ECL method with exposure to Hyperfilm MP. 
3. Results 
3.1. Immunoprecipitation ofaPAK 
Four bands of approx. 62, 65, 68 and 76 kDa were detected 
on Western blots of total myocyte extracts probed with aPAK 
antibodies (Fig. 1A). This antibody immunoprecipitated only 
the 65 and 68 kDa proteins from cell extracts and the immu-
noprecipitation was quantitative (Fig. IB). The 65 and 68 kDa 
bands were not detected when the immunoprecipitation pro-
cedure was carried out in the absence of antibody or with 
antibody in the presence of competing peptide (Fig. 1C). 
These data indicate that the immunoprecipitation of the 65 
and 68 kDa doublet was specific and represents rxPAK. The 
62 and 76 kDa bands detected on Western blots may repre-
sent either non-specific proteins detected only in the denatured 
state, or proteins related to aPAK for which the antibody has 
a lower affinity. 
3.2. Activation of aPAK by hyperosmotic shock 
aPAK activities were assayed after immunoprecipitation 
from myocyte extracts using MBP as substrate. In the absence 
of precipitating antibody, there was minimal phosphorylation 
of MBP (Table 1). Immunoprecipitation of aPAK and sub-
sequent assay showed a high basal level of aPAK activity in 
unstimulated (no medium change) myocytes (Table 1). Re-
placing the medium with fresh serum-free medium did not 
induce any significant further increase in ocPAK activity at 
1 min, but there was an increase in activity in cells subjected 
to 0.5 M sorbitol in the presence or absence of 0.2 u,M 
okadaic acid (Table 1, Fig. 2). In both control cells and cells 
subjected to hyperosmotic shock, phosphorylation of MBP 
was essentially abolished when the immunoprecipitation pro-
cedure was carried out in the presence of competing peptide 
(Table 1). Assay of aPAK in control and stimulated cells was 
therefore specific. 
Although in control cells exposed to fresh serum-free me-
dium there was no increase in rxPAK activity above basal 
levels at 1 min, by 3 min there was a slight increase in activity 
(122±3%, p<0.05) which was sustained up to 15 min (Fig. 
2). Hyperosmotic shock (0.5 M sorbitol) in conjunction with 
Table 1 
aPAK immunokinase assays 
No antibody 
Unstimulated (no medium change) 
Control (1 min after medium change) 
0.5 M sorbitol (1 min) 
Fig. 1. Western blots of aPAK in myocyte extracts. (A) Total ex-
tract (50 ug protein) was immunoblotted for aPAK. The position 
of the 66 kDa molecular mass marker is shown on the right. (B) 
Immunoblots of aPAK in the immunoprecipitate (IP) and immuno-
depleted supernatant (SN). (C) Specificity of aPAK immunoprecipi-
tation using the competing peptide epitope. 
okadaic acid (0.2 uM) potently activates the SAPKs/JNKs in 
ventricular myocytes (A. Clerk and P.H. Sugden, unpub-
lished). Exposure of cells to sorbitol+okadaic acid induced a 
rapid increase in aPAK activity within 30 s (144 ±6%), which 
was maximal by 3 min (187 ±7%) and sustained over 15 min 
(Fig. 2). ET-1 and IL-lß also activate SAPKs/JNKs in these 
myocytes ([7], and A. Clerk and P.H. Sugden, unpublished). 
However, neither agonist increased ocPAK activity signifi-
cantly above control levels at either 3 or 15 min (data not 
shown). 
aPAK activity (cpm 32P incorporated into MBP) 
No peptide +peptide 
2 546 n.d. 
44177 n.d. 
48011 4484 
67 519 4734 
aPAK activity was measured as described in Section 2. To ensure assay specificity, immunoprecipitations were carried out in the presence of the 
competing peptide. A single representative experiment (out of two independent experiments) is shown, n.d., not determined. 
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Fig. 2. Time course of aPAK activation by sorbitol+okadaic acid. 
Myocytes were incubated under control conditions (o) or were ex-
posed to 0.5 M sorbitol+0.2 |xM okadaic acid (•). aPAK was as-
sayed by an immunokinase method as described in Section 2. The 
media were changed in both incubations. 
4. Discussion 
The apparent relative molecular mass of aPAK on SDS 
gels is 65-68 kDa ([10,11] and Fig. 1A). The antibody used 
here was specific for ocPAK with no cross-reactivity with 
ßPAK or yPAK according to the suppliers (Santa Cruz Bio-
technology). Of the four bands detected on Western blots of 
myocyte extracts, only the 65 and 68 kDa proteins blots were 
detected after immunoprecipitation (Fig. IB). These bands 
were specific (they were not detected when competing peptide 
was included in the immunoprecipitation, Fig. 1C) and prob-
ably represent the two forms of aPAK previously identified 
[10]. The 68 kDa protein may be a phosphorylated form of 
aPAK, which has a reduced mobility compared with the non-
phosphorylated form [11]. However, the relative levels of the 
65 and 68 kDa proteins did not change on exposure of the 
cells to hyperosmotic shock (data not shown). Thus, if the 68 
kDa protein is a phosphorylated form of aPAK, hyperos-
motic shock did not increase its level of phosphorylation. 
ocPAK is highly expressed in brain [10], but has also been 
identified in COS-7 and Swiss 3T3 cells in association with 
the Nek adaptor protein [17], and in neutrophils [18]. Here, 
we have detected aPAK in cultured ventricular myocytes. We 
have not been able to ascertain the abundance relative to 
other PAK isoforms because of lack of suitable antibodies. 
There have been few studies on activation of PAKs. Cdc42/ 
Racl inducible autophosphorylation and activation of re-
combinant PAKs expressed in a variety of cells has been dem-
onstrated in vitro and in vivo using MBP as a substrate 
[11,12,19-21]. However, endogenous PAK activation has so 
far only been demonstrated in platelets, where thrombin 
(which binds to a G-protein coupled receptor) activates 
yPAK within 30 s [13]. Our study of aPAK in neonatal ven-
tricular myocytes has shown a high basal level of activity of 
this isoform in unstimulated myocytes. The Rho-family of 
small G proteins are implicated in re-organisation of the cy-
toarchitecture (reviewed [22]). It may be that they (and con-
sequently ocPAK) are activated in these neonatal myocytes 
which, in culture, are continually undergoing cytoskeletal/ 
myofibrillar reorganisation. 
Despite the high basal activity of ocPAK, hyperosmotic 
stress combined with okadaic acid induced further activation 
of the kinase (almost 2-fold, Fig. 2). The rapid and sustained 
activation of ocPAK (maximal within 3 min) is consistent its 
putative role in SAPK/JNK activation (detectable from 5 min, 
sustained over 4 h [7]). In contrast, neither ET-1 (which, like 
thrombin, acts through a G protein-coupled receptor [23]) nor 
IL-Iß increased the activity of aPAK, although both agonists 
stimulate the SAPKs/JNKs in myocytes in culture ([7] ; and A. 
Clerk and P.H. Sugden, unpublished). The receptors for these 
agonists presumably couple to the SAPK/JNK cascade either 
through different PAK isoforms, or using different proteins 
entirely. Other proteins implicated in the activation of the 
SAPK/JNK cascade include the mixed lineage kinases and 
germinal center kinase (reviewed [4]), which remain to be in-
vestigated. 
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